Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9006019 | 1.00 | EPHX1 (0.43) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL4778608 | 0.87 | CA1 (0.41) | EPHX1ACHEALDH1A1 | |
| SCHEMBL1696818 | 0.86 | CA1 (0.46) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL20683487 | 0.86 | CA1 (0.46) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL2344660 | 0.85 | EPHX1 (0.44) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL5199004 | 0.83 | EPHX1 (0.43) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL7372859 | 0.83 | EPHX1 (0.43) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL4727557 | 0.83 | EPHX1 (0.43) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL5782797 | 0.83 | EPHX1 (0.43) | EPHX1ACHEALDH1A1NPC1RAB9A | |
| SCHEMBL7453134 | 0.83 | EPHX1 (0.43) | EPHX1ACHEALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362868-A2 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2361243-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Virobay, Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-2200609-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010062590-A2 | PROCESS FOR THE PREPARATION OF PROTECTED L-ALANINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010056877-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |